BRTX - EXCLUSIVE: Stem Cell Focused BioRestorative Ventures Into $63B Aesthetics Market Via Supply Agreement With Evolutionary Biologics | Benzinga
BioRestorative Therapies Inc (NASDAQ: BRTX) has entered into a supply agreement with Evolutionary Biologics, a supplier of biologic-based cosmetics.
Under the supply agreement, BioRestorative, using its cGMP ISO-7 certified clean room, will manufacture tissue-based biologics for Evolutionary Biologics for cosmetic and aesthetic applications.
The initial order of 5,000 vials represents a controlled launch and is expected to have a positive financial impact.
The first-generation product formulated and manufactured is an umbilical cord tissue extract that is highly enriched with factors that address the signs of aging.
These ...